Literature DB >> 1881724

Use of western blot and enzyme-linked immunosorbent assays to assist in the diagnosis of Lyme disease.

C D Rose1, P T Fawcett, B H Singsen, S B Dubbs, R A Doughty.   

Abstract

Without evidence of erythema chronicum migrans, diagnostic confirmation of Lyme disease may be difficult, particularly if there are conflicting laboratory results. Often, for families and physicians, the clinical dilemma is whether fatigue, arthritis/arthralgias, a positive enzyme-linked immunosorbent assay (ELISA), and tick exposure, but no evidence of erythema chronicum migrans, are sufficient to diagnose and treat Lyme disease. Patients with discordant ELISA and Western blot (WB) assay results for Borrelia burgdorferi were studied to determine whether there was sufficient clinical evidence to support a diagnosis of Lyme disease. Of 650 consecutive sera analyzed by ELISA in a laboratory within a 1-year period, 77 were subsequently tested by WB. The clinical data from these patients were then analyzed. The study population was divided into three groups: group 1 (positive ELISA, positive WB), group 2 (positive ELISA, negative WB), and group 3 (negative ELISA, negative WB). Findings included the following: (1) Patients with a strong clinical history of Lyme disease were usually positive by both WB and ELISA (group 1). (2) All patients with erythema chronicum migrans had both positive WB and ELISA tests. (3) Ninety-one percent of group 2 had a rheumatic or inflammatory condition other than Lyme disease. (4) A definite response to antibiotics occurred in 75% of patients wherein both ELISA and WB were positive but in only 11% of cases with a positive ELISA but a negative WB. (5) History of tick exposure and degree of fever were not significantly different among the three serologic groups, and thus they were not diagnostically helpful.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1881724

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  9 in total

1.  Identifying diagnostic peptides for lyme disease through epitope discovery.

Authors:  G A Kouzmitcheva; V A Petrenko; G P Smith
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

2.  Western Blot as a confirmatory test for Lyme disease.

Authors:  H Artsob
Journal:  Can J Infect Dis       Date:  1993-03

3.  Comparison of immunodot and western blot assays for diagnosing Lyme borreliosis.

Authors:  P T Fawcett; C D Rosé; K M Gibney; R A Doughty
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

4.  Immunoblot interpretation criteria for serodiagnosis of early Lyme disease.

Authors:  S M Engstrom; E Shoop; R C Johnson
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

5.  Evaluation of a passive hemagglutination assay as screening test and of a recombinant immunoblot as confirmatory test for serological diagnosis of Lyme disease.

Authors:  A Hamann-Brand; M Flondor; V Brade
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-07       Impact factor: 3.267

6.  Reinfection in paediatric Lyme borreliosis.

Authors:  C D Rose; P T Fawcett; J D Klein; S C Eppes; G M Caputo; R A Doughty
Journal:  Ann Rheum Dis       Date:  1993-09       Impact factor: 19.103

7.  Correlation of seroreactivity with response to antibiotics in pediatric Lyme borreliosis.

Authors:  P T Fawcett; C D Rosé; K M Gibney; R A Doughty
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

8.  Response of soluble IL-2 receptor, interleukin-2 and interleukin-6 in patients with positive and negative Borrelia burgdorferi serology.

Authors:  I Nilsson; M Alves; L Nässberger
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

9.  Comparison of four immunoserologic assays for detection of antibodies to Borrelia burgdorferi in patients with culture-positive erythema migrans.

Authors:  P D Mitchell; K D Reed; T L Aspeslet; M F Vandermause; J W Melski
Journal:  J Clin Microbiol       Date:  1994-08       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.